Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
The New England Journal of Medicine|September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part SarcomaAlice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary TumorsAndrea B Apolo, Daniel M Girardi, Scot A Niglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2021
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)Helen X Chen, Minkyung Song, Holden T Maecker, et al.
The New England Journal of Medicine|July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
The New England Journal of Medicine|September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part SarcomaAlice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary TumorsAndrea B Apolo, Daniel M Girardi, Scot A Niglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2021
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)Helen X Chen, Minkyung Song, Holden T Maecker, et al.
The New England Journal of Medicine|July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 20